Acrux begins anti-nausea trial
Wednesday, 02 March, 2005
Acrux (ASX:ACR) has commenced dosing in a Phase I clinical trial utilising its MDTS transdermal spray to deliver anti-nausea drug granisetron. The pharmacokinetics trial will compare absorption of the drug, which is used to treat nausea in chemotherapy patients, against that of an oral formulation in six healthy volunteers.
"Prevention of nausea during chemotherapy with a product that does not require injections or tablets would help minimise distress for cancer patients," said Acrux CEO Igor Gonda. Brisbane-based CRO Q-Pharm is conducting the trial in its clinical trials facilities at the Royal Brisbane Hospital for Acrux subsidiary Acrux DDS.
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
Melanoma-causing mutation can lie dormant in healthy skin
Researchers found many examples of the mutation in normal skin, including skin next to a mole and...
